Research Article

Labelling and Clinical Performance of Human Leukocytes Labelled with 99mTc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent

Table 1

Summary of clinical results of patients with WBCs prepared using HES-Leukokit® or Gelofusine-Leukokit®.

Accuracy (%)Sensitivity (%)Specificity (%)PPV (%)NPV (%)

HESOsteomyelitis ()87.55010010085.7
Hip prosthesis ()84.610083.333.3100
Vascular grafts ()100100100100100
Knee prosthesis ()9510094.466.7100
All ()90.9 (74.9–96.1)83.3 (22.3–95.7)92.1 (78.1–98.3)62.5 (18.4–90.1)97.2 (81.3–99.3)

GelofusineOsteomyelitis ()100100100100100
Hip prosthesis ()93.866.710010092.9
Vascular grafts ()100100100100100
Knee prosthesis ()100100100100100
All ()98.3 (90.8–100)91.7 (61.5–99.8)100 (92.3–100)100 (71.5–100)97.9 (88.7–99.9)

All values are expressed as percentage, and the confidence intervals are given in brackets.